Ivonescimab (Anti-PD-1 & VEGF)

製品コードA4054 別名: CD279， VEGFA

Ivonescimab is a first-in-class humanized tetravalent bispecific antibody targeting PD-1 and VEGF-A, with immune checkpoint inhibitory, anti-angiogenic, and antineoplastic activities. It is being developed for the treatment of non-small cell lung cancer (NSCLC) and other solid tumors, including breast, liver, and gastric cancers. M.W 201.12 kDa

サイズ（液体）	価格(税別)	在庫状況
1mg	JPY 70500	国内在庫なし

代表番号: 045-509-1970\|電子メール：sales@selleck.co.jp よく尋ねられる質問

質量管理及び製品安全説明書

PD-1/PD-L1阻害剤の選択性比較

生物活性

製品説明	Ivonescimab is a first-in-class humanized tetravalent bispecific antibody targeting PD-1 and VEGF-A, with immune checkpoint inhibitory, anti-angiogenic, and antineoplastic activities. It is being developed for the treatment of non-small cell lung cancer (NSCLC) and other solid tumors, including breast, liver, and gastric cancers. M.W 201.12 kDa

製品説明

CAS No.	2428381-53-5
Source	CHO
Storage (From the date of receipt)	-80℃(avoid freeze-thaw cycles)
Shipping	Shipped under low temperature conditions

各種クローンの論文数比較

^*Selleckは、市場の主要なクローンを収集し、2024年9月までの文献での使用状況を調査しました。その結果、Selleckの選定クローンが最も広く使用されていることが示されました。

臨床試験

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07743632	NOT_YET_RECRUITING	Drug: Carboplatin\|Drug: Docetaxel\|Drug: Doxorubicin\|Drug: Cy	Breast Cancer; Triple Negative Breast Cancer	University of Kansas Medical Center	2026-09	PHASE2
NCT07234877	NOT_YET_RECRUITING	Drug: Ivonescimab\|Drug: Carboplatin\|Drug: Pemetrexed\|Drug: P	Non Small Cell Lung Cancer	European Organisation for Research and Treatment of Cancer - EORTC	2026-11	PHASE2
NCT07753824	NOT_YET_RECRUITING	Drug: Ivonescimab\|Drug: IP PTX	Phase II; Ivonescimab; Intraperitoneal; Paclitaxel; High Grade Metastatic; Appendiceal Adenocarcinoma	M.D. Anderson Cancer Center	2027-01-16	PHASE2
NCT07565389	NOT_YET_RECRUITING	Drug: Ivonescimab 20 mg/kg	Nasopharyngeal Carcinoma (NPC)	National University Hospital, Singapore	2026-05	PHASE2
NCT01042379	RECRUITING	Drug: Standard Therapy\|Drug: AMG 386 with or without Trastuz	Breast Neoplasms; Breast Cancer; Breast Tumors; Angiosarcoma; TNBC - Triple-Negative Breast Cancer; HER2-positive Breast Cancer; HER2-negative Breast Cancer; Hormone Receptor Positive Tumor; Hormone Receptor Negative Tumor; Early-stage Breast Cancer; Locally Advanced Breast Cancer	QuantumLeap Healthcare Collaborative	2010-03-01	PHASE2
NCT07264075	RECRUITING	Drug: Ivonescimab 10 mg/kg\|Drug: Ligufalimab\|Drug: Pembroliz	Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)	Groupe Oncologie Radiotherapie Tete et Cou	2026-05-05	PHASE3

(data from https://clinicaltrials.gov, updated on 2026-08-04)

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須